Coya Therapeutics (NASDAQ:COYA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Coya Therapeutics (NASDAQ:COYA) from a sell rating to a hold rating in a report published on Saturday morning.

COYA has been the topic of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, October 8th. D. Boral Capital restated a “buy” rating and set a $15.00 price target on shares of Coya Therapeutics in a report on Wednesday, November 12th. Lake Street Capital reaffirmed a “buy” rating and issued a $17.00 price target on shares of Coya Therapeutics in a research report on Wednesday, November 5th. Chardan Capital reissued a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Friday. Finally, HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, August 25th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Coya Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Coya Therapeutics Stock Performance

Shares of COYA stock opened at $5.85 on Friday. Coya Therapeutics has a fifty-two week low of $4.65 and a fifty-two week high of $8.29. The company has a 50 day moving average price of $6.07 and a 200 day moving average price of $6.04. The stock has a market capitalization of $122.38 million, a P/E ratio of -5.27 and a beta of 0.20.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%.The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $3.70 million. On average, research analysts forecast that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Coya Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Prosperity Wealth Management Inc. increased its stake in Coya Therapeutics by 16.4% in the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock valued at $136,000 after purchasing an additional 3,350 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Coya Therapeutics in the 3rd quarter valued at $28,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Coya Therapeutics in the 1st quarter valued at $65,000. Jane Street Group LLC grew its position in shares of Coya Therapeutics by 101.7% in the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock valued at $169,000 after buying an additional 13,176 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in Coya Therapeutics during the 2nd quarter worth $119,000. 39.75% of the stock is owned by institutional investors and hedge funds.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.